DIA: Driving Insights to Action – Details, episodes & analysis

Podcast details

Technical and general information from the podcast's RSS feed.

DIA: Driving Insights to Action

DIA

Science

Health & Fitness

Frequency: 1 episode/44d. Total Eps: 20

DIA is a global, multidisciplinary, membership association of healthcare professionals that works towards the advancement of lifesaving medicines, therapies, and technologies around the world.

Site

RSS

Apple

Recent rankings

Latest chart positions across Apple Podcasts and Spotify rankings.

Apple Podcasts

🇬🇧 Great Britain - lifeSciences
10/09/2025
#97
🇬🇧 Great Britain - lifeSciences
09/09/2025
#77
🇬🇧 Great Britain - lifeSciences
08/09/2025
#69
🇬🇧 Great Britain - lifeSciences
07/09/2025
#59

Shared links between episodes and podcasts

Links found in episode descriptions and other podcasts that share them.

See all

https://notebooklm.google/
2 shares
https://globalforum.diaglobal.org/
2 shares
https://www.diaglobal.org/en/flagship/dia-2023
2 shares

RSS feed quality and score

Technical evaluation of the podcast's RSS feed quality and structure.

See all

RSS feed quality

To improve

Score global : 42%

Publication history

Monthly episode publishing history over the past years.

Year

Latest published episodes

Recent episodes with titles, durations, and descriptions.

See all

DIA: Your Partner in Life Sciences Training and Development

Episode 199

Wednesday, November 6, 2024 • Duration 14:16

This podcast by the Drug Information Association (DIA) highlights the significant benefits of investing in professional development programs for employees in the life sciences industry. They emphasizes how training and development initiatives accelerate product development, improve employee retention, and foster a strong workplace culture. It showcases DIA’s commitment to providing comprehensive learning solutions that address specific industry needs and equip professionals with the skills and knowledge necessary for success.

Reach out to business.solutions@diaglobal.org for more information.

Audio generated by NotebookLM, OpenAI, October 29, 2024, https://notebooklm.google/

Read moreCollapse

DIA: Going Beyond the Traditional Definition of Drug Development

Episode 198

Wednesday, May 29, 2024 • Duration 01:56

In this DIA 60th anniversary interview, former Board President Ling Su shares his thoughts on the two most important aspects of DIA’s future for the next generation of members.

ANVISA Explains Innovative Online Optimized Assessment Project

Episode 189

Tuesday, March 14, 2023 • Duration 14:44

For regulators in Brazil, the pandemic’s aftermath includes a backlog of post-approval changes, delayed by emergency development of COVID-19 vaccines and therapies, related to biologic product quality. ANVISA’s new Online Optimized Assessment Project has significantly resolved these pending requests. “The pandemic had already enabled use of online tools for remote assessment of applications and virtual meetings between ANVISA and applicants, and also helped us be closer to other reference regulatory authorities in the process of building trust,” explains project architect Elkiane Macedo Rama, an Adviser of ANVISA’s Third Directorate. “The Online Optimized Assessment Project was a way to gather all these tools in a strategy to speed up the review process of these applications.”

Read moreCollapse

Australian Clinical Trials Alliance Part 1 – Current Perceptions

Episode 188

Monday, March 6, 2023 • Duration 12:33

“The pandemic had a substantial impact on community understanding of clinical trials. Having said that, the sort of ambient level of community knowledge of clinical trials is still substantially lower than it needs to be,” explains Australian Clinical Trials Alliance Board Chair Steve Webb. “Community awareness of the difference between evaluation of experimental interventions, about which relatively little is known regarding safety and effectiveness, compared with comparative effectiveness research, is an important distinction often with limited understanding in the community, in government, and amongst policymakers.”

Read moreCollapse

Looking Back and Ahead: Translational Science Advances Impacting Patient Care

Episode 187

Monday, December 19, 2022 • Duration 29:27

From microphysiological systems and digital pathology to next-generation-sequencing and diversity in foundational genomic data sets: In this iteration of our annual year in review podcast, Global Forum Co-Editors for Translational Science Gary Kelloff and Lanny Kirsch discuss emergent technologies and approaches that are upending clinical development, diagnostic, and patient care in oncology and beyond.

Read moreCollapse

Rwanda Welcomes African Medicines Agency Home

Episode 186

Wednesday, November 30, 2022 • Duration 43:29

While the African Medicines Agency (AMA) plans and plants its inaugural headquarters in Rwanda, the European Commission, the European Medicines Agency (EMA), several EU Member States, and the Bill and Melinda Gates Foundation continue to mobilize more than €100 million in support. “The idea is to use the AMA as a platform that will further advance the capacities of the African continent to regulate medical products as a collective. It's a network approach to regulation of medical products on the continent,” explains David Mukanga (Deputy Director, Africa Regulatory Systems, Bill and Melinda Gates Foundation) in this conversation with EMA Head of International Affairs Martin Harvey Allchurch.

Read moreCollapse

Will Technology Solve the Research “People Problem”?

Episode 185

Tuesday, November 22, 2022 • Duration 20:18

Clinical trials struggle to enroll eligible patients, while interested patients have difficulty finding pertinent clinical trials. Can technology help solve this people problem? “Typical patient recruitment happens based on historical data at research sites and that usually does not help, given the number of competing clinical trials trying to reach out to the same patients,” explains Indegene Senior Vice President for Enterprise Clinical Solutions Ram Yeleswarapu. “But today, tools and techniques to mine electronic health record data, clinical data, molecular data, allow us to look at sites and patients in a much more precise manner.”

Read moreCollapse

Why Trans/Nonbinary Research Benefits All Communities

Episode 184

Friday, November 18, 2022 • Duration 34:56

Actions to increase patient diversity in clinical research initially addressed racial and ethnic demographics but are expanding to address gender identity. “Further research can only help us better understand the differences in our bodies and illnesses and how combinations of certain medications and existing treatments can improve everyone's lives,” explains Liam Paschall (Parexel, TransCanWork, DEIBA thought leader). “This will not only help transgender people. It's going to teach us about how the human body works.”

Read moreCollapse

Digital Revolutionizing Data-Driven Reimbursement

Episode 183

Thursday, October 20, 2022 • Duration 27:05

Digital technologies are rippling through clinical research and care, promising deeper links between healthcare research and delivery. In her interview with Global Forum US Editor Ebony Dashiell-Aje (BioMarin), Digital Medicine Society CEO Jennifer Goldsack expresses concern about the lag between producing evidence that something is fit for purpose and the conversations that need to take pace with payers and HTA experts. “We don't want to demonstrate, using the best, most novel measures possible, that new therapies are making a meaningful change for patients in ways that we haven't been able to measure before but are critically important, then delay going to market because additional evidence is required by our payer colleagues because we haven't taken time to take them with us.”

Read moreCollapse

China Sets New Record for Local Drug Approvals in 2021

Episode 182

Thursday, September 15, 2022 • Duration 17:07

DIA Global Forum’s annual review of new drug approvals in China has shown growth in both the number and types of new drugs approved in China from 2019 through 2021: from 34 new chemical drugs and 19 biological products in 2019 to 37 new chemical drugs and 24 biological products in 2021. This podcast explores this growth in the context of the regulatory reform begun in China in 2015. “The annual number of new drug approvals reached a record high of 61 in 2021,” explains Global Forum China Regional Editor Ling Su (Shenyang Pharmaceutical University Yeehong Business School; Venture Partner, Lilly Asia Ventures). “In 2021, among the 61 new drugs approved, 31–slightly over 50 percent–were developed by local companies, and this was the first time that domestic companies received more new drug approvals than foreign companies in a given year.”

Read moreCollapse

DIA: Driving Insights to Action – Details, episodes & analysis

Podcast details

Recent rankings

Apple Podcasts

Shared links between episodes and podcasts

RSS feed quality and score

Publication history

Latest published episodes

Related Shows Based on Content Similarities

Apple Podcasts

Related Shows Based on Content Similarities

Spotify

DIA: Driving Insights to Action – Details, episodes & analysis

Podcast details

Recent rankings

Apple Podcasts

Shared links between episodes and podcasts

Other9

Youtube1

RSS feed quality and score

Publication history

Latest published episodes

Similar podcasts and content

Related Shows Based on Content Similarities

Apple Podcasts

Related Shows Based on Content Similarities

Other9

Youtube1

Spotify